We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

100 hedge funds and large institutions have $1.23B invested in Ultragenyx Pharmaceutical in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 23

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

0% more funds holding

Funds holding: 100 → 100 (0)

14% less call options, than puts

Call options by funds: $342K | Put options by funds: $399K

18% less capital invested

Capital invested by funds: $1.5B → $1.23B (-$271M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
100
Holders Change
–
Holders Change %
0%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
39
Reduced
23
Closed
18
Calls
$342K
Puts
$399K
Net Calls
-$57K
Net Calls Change
-$1.98M

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$18.4M
2
Millennium Management
Millennium Management
New York
+$13.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.58M

Top Sellers

Rank Fund Capital Flow
1
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$22.9M
2
CWAM
Columbia Wanger Asset Management
Illinois
-$21.1M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$6.88M
4
GC
Guggenheim Capital
Illinois
-$3.79M
5
DCM
Driehaus Capital Management
Illinois
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
51
BlackRock Investment Management
Delaware
$2.03M -$4.26K -93 -0.2%
MSA
52
Mason Street Advisors
Wisconsin
$1.96M – – –
Charles Schwab
53
Charles Schwab
California
$1.83M +$109K +2,376 +6%
TG
54
TCW Group
California
$1.65M -$459K -10,009 -21%
TCIM
55
TIAA CREF Investment Management
New York
$1.49M +$32K +699 +2%
HCM
56
Highbridge Capital Management
New York
$1.28M +$1.34M +29,292 New
CCI
57
Columbus Circle Investors
$1.23M +$1.28M +28,037 New
UOC
58
UBS O'Connor
Illinois
$1.1M +$1.15M +25,000 New
TC
59
TFS Capital
Pennsylvania
$1.09M +$1.14M +24,889 New
Ameriprise
60
Ameriprise
Minnesota
$1.09M -$987K -21,547 -47%
ProShare Advisors
61
ProShare Advisors
Maryland
$993K +$1.04M +22,633 New
TD Asset Management
62
TD Asset Management
Ontario, Canada
$984K +$163K +3,550 +19%
CS
63
Credit Suisse
Switzerland
$889K +$408K +8,913 +79%
Swiss National Bank
64
Swiss National Bank
Switzerland
$842K +$591K +12,900 +205%
TI
65
Trexquant Investment
Connecticut
$675K +$706K +15,400 New
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
$572K +$2.52K +55 +0.4%
FSA
67
Franklin Street Advisors
North Carolina
$543K -$117K -2,550 -17%
SCA
68
Secor Capital Advisors
New York
$507K +$530K +11,564 New
RFS
69
Rockefeller Financial Services
New York
$497K -$47.7K -1,040 -8%
GCP
70
GSA Capital Partners
United Kingdom
$472K +$492K +10,748 New
CSS
71
Cubist Systematic Strategies
Connecticut
$459K +$479K +10,452 New
Macquarie Group
72
Macquarie Group
Australia
$433K – – –
UBS Group
73
UBS Group
Switzerland
$419K +$438K +9,552 New
State of New Jersey Common Pension Fund D
74
State of New Jersey Common Pension Fund D
New Jersey
$412K – – –
TA
75
Teachers Advisors
New York
$412K – – –
1 2
3
4 5

RARE Hedge Fund Activity: Q4 2014 in Review

100 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2014, worth a combined $1.23B — down 18% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RARE positions and 18 closed out — a net gain of 2 holders — while 39 added to existing stakes and 23 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $18.4M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $22.9M.

  • 100 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $1.23B of Ultragenyx Pharmaceutical stock for Q4 2014, down 18% quarter-over-quarter.
  • 20 funds opened new Ultragenyx Pharmaceutical positions in Q4 2014 and 18 closed out, a net change of +2 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $18.4M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2014 was TPG Group Holdings (SBS) Advisors, an estimated $22.9M sold.

Based on aggregated 13F filings for Q4 2014.